Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3876357 | 0.90 | HTR1A (0.56) | HTR1AGRIN2BSIGMAR1 | |
| SCHEMBL3881136 | 0.82 | KDM4E (0.64) | GRIN2BKDM4E | |
| SCHEMBL1415530 | 0.81 | HTR1A (0.81) | HTR1AGRIN2BSIGMAR1KDM4E | |
| SCHEMBL3886166 | 0.79 | BAZ2B (0.52) | HTR1AGRIN2BSIGMAR1 | |
| SCHEMBL7996548 | 0.79 | BAZ2B (0.49) | GRIN2BSIGMAR1KDM4E | |
| SCHEMBL20145479 | 0.76 | HTR1A (0.80) | HTR1AGRIN2BSIGMAR1 | |
| SCHEMBL16624100 | 0.75 | HTR1A (0.50) | HTR1AGRIN2BSIGMAR1KDM4E | |
| SCHEMBL17993875 | 0.74 | MEN1 (0.55) | HTR1AGRIN2BSIGMAR1 | |
| SCHEMBL25774052 | 0.73 | HTR7 (0.54) | HTR1AKDM4E | |
| SCHEMBL4944193 | 0.73 | HTR1A (0.97) | HTR1AGRIN2BSIGMAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486984-B2 | Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO., KG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20110144146-A1 | Aminomethyl Substituted Bicyclic Aromatic Compounds Suitable for Treating Disorders That Respond to Modulation of the Dopamine D3 Receptor | ABBOTT GMBH & CO. KG | 2011-06-16 | — | — | US | disclosed |
| EP-1809598-B1 | AMINOMETHYL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-03-16 | — | — | EP | disclosed |
| EP-1809598-A1 | AMINOMETHYL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006040180-A1 | AMINOMETHYL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144146-A1 | Aminomethyl Substituted Bicyclic Aromatic Compounds Suitable for Treating Disorders That Respond to Modulation of the Dopamine D3 Receptor | CHRNA3, HCRTR2, CRHR2 | HTR1A 118/4885GRIN2B 223/4885SIGMAR1 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.